All In Biotech

Free tool

FAERS Monitor: Myoview

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020372 or its brand name (Myoview, Technetium Tc-99m Tetrofosmin Kit). Reports on generic versions are filed under their own applications.

Reports

700

Serious

170

24% of reports

Hospitalization

55

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event409
  • radioisotope scan abnormal274
  • drug ineffective152
  • product quality issue29
  • dizziness21
  • headache21
  • nausea20
  • hypersensitivity16
  • scan myocardial perfusion abnormal16
  • urticaria16
  • vomiting16
  • dyspnoea15
  • pruritus15
  • chills12
  • hyperhidrosis12

Reports by year received

View as table
YearReports
20044
20055
20065
20075
20089
20096
20109
20117
20126
20138
201417
201520
201635
201737
201836
201983
202091
202157
202238
202329
202428
202559
2026106

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,459 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
radioisotope scan abnormalSignal27419032.216679.93,181,922
scan myocardial perfusion abnormalSignal163487.12089.246,894
no adverse eventSignal40968.063.827,097
product quality issueSignal296.44.5128
drug ineffectiveSignal1523.53.0282
chillsSignal123.11.815
urticariaSignal162.91.818
hyperhidrosisSignal122.81.612
hypersensitivitySignal162.61.614
dizziness211.30.81
pruritus151.20.70
vomiting161.00.60
headache211.00.70
dyspnoea150.80.51
nausea200.80.51

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.